However, further studies are necessary to confirm the predictive value of CCL5 for the development of resistance to FLT3 inhibitors in FLT3‐mutated AML and to delineate the significance of receptor binding and its precise effect on downstream signaling. The gene discussed is FLT3; the disease is acute myeloid leukemia.